Bifeprunox
- Generic Name
- Bifeprunox
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N3O2
- CAS Number
- 350992-10-8
- Unique Ingredient Identifier
- AP69E83Z79
- Background
Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
- Indication
Bifeprunox is being evaluated for the treatment of schizophrenia, psychosis, and Parkinson's disease.
- Associated Conditions
- -
- Associated Therapies
- -
Bifeprunox Extension to Extension Study in Patients With Schizophrenia
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 11
- Registration Number
- NCT00861497
- Locations
- ๐ฎ๐น
IT001, Brescia, Italy
Efficacy of Bifeprunox in Patients With Schizophrenia
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2010-09-27
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 346
- Registration Number
- NCT00704509
- Locations
- ๐ฎ๐ณ
IN006, Chennai, India
๐ฎ๐ณIN008, Ahmedabad, India
๐ฎ๐ณIN011, Ahmedabad, India
Efficacy of Bifeprunox in Patients With Schizophrenia
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2010-09-27
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 227
- Registration Number
- NCT00658645
- Locations
- ๐ท๐บ
RU017, Chita, Russian Federation
๐ท๐บRU005, Moscow, Russian Federation
๐ท๐ดRO002, Bucuresti, Romania
Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects
- First Posted Date
- 2007-12-27
- Last Posted Date
- 2009-07-10
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 144
- Registration Number
- NCT00581451
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 83
- Registration Number
- NCT00396214
- Locations
- ๐บ๐ธ
Site 311, Santa Ana, California, United States
๐บ๐ธSite 330, Atlanta, Georgia, United States
๐บ๐ธSite 370, Decatur, Georgia, United States
Study Evaluating Bifeprunox in Patients With Schizophrenia.
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT00366327
Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT00366704
Open Label Extension Study of Bifeprunox
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2007-12-27
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00366171
Study Evaluating Bifeprunox in Bipolar Depression
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2007-12-05
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 380
- Registration Number
- NCT00245973
Patient-reported Outcomes in the Treatment of Schizophrenia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-03
- Last Posted Date
- 2013-09-12
- Lead Sponsor
- Solvay Pharmaceuticals
- Registration Number
- NCT00230828
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath